[Renal denervation in patients with resistant hypertension: is it still possible to resuscitate?].
Transcatheter renal denervation (RDN) has been markedly applied and developed in clinical practice in past five years and not only for patients with resistant hypertension. The issue that more than 50% patients with so-called resistant hypertension are in fact patients without adherence to this type of mediation has not been resolved in RDN trials till now. The study Symplicity HTN-3 showed no differences in blood pressure change between the patients with RDN and group of patients after false procedure who continued in their drug therapy. Future of RDN is more than questionable and there is a need to return to animal studies that will verify the real effectiveness of RDN, subsequently, will redefine population of patients indicated for RDN and confirm the applicability of newly developed techniques.